Joel Isaacson & Co., LLC Halozyme Therapeutics, Inc. Transaction History
Joel Isaacson & Co., LLC
- $2.07 Billion
- Q3 2024
A detailed history of Joel Isaacson & Co., LLC transactions in Halozyme Therapeutics, Inc. stock. As of the latest transaction made, Joel Isaacson & Co., LLC holds 10,462 shares of HALO stock, worth $507,093. This represents 0.03% of its overall portfolio holdings.
Number of Shares
10,462
Previous 10,462
-0.0%
Holding current value
$507,093
Previous $547,000
9.32%
% of portfolio
0.03%
Previous 0.03%
Shares
3 transactions
Others Institutions Holding HALO
# of Institutions
544Shares Held
125MCall Options Held
294KPut Options Held
180K-
Black Rock Inc. New York, NY17.6MShares$854 Million0.02% of portfolio
-
Vanguard Group Inc Valley Forge, PA12.9MShares$625 Million0.01% of portfolio
-
State Street Corp Boston, MA6.63MShares$322 Million0.02% of portfolio
-
Snyder Capital Management L P San Francisco, CA4.06MShares$197 Million5.07% of portfolio
-
Alliancebernstein L.P. New York, NY3.41MShares$165 Million0.07% of portfolio
About HALOZYME THERAPEUTICS, INC.
- Ticker HALO
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 139,288,992
- Market Cap $6.75B
- Description
- Halozyme Therapeutics, Inc. operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable...